Objectives: This study examined the efficacy and safety of rituximab in children with chronic immune thrombocytopenic purpura.Study design: Twenty-four patients, 2 to 19 years of age, with platelet counts 150,000/mcL was achieved; partial (PR) if 50,000 to 150,000/mcL; minimal (MR) if the count increased by >20,000/mcL to a peak count >30,000/mcL but 50%CR rate lasting an average of 13 months, with 9 of 15 CRs ongoing (8 lasted 6 months or longer).There was no substantial toxicity other than transient serum sickness.
展开▼
